Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KB301 · 1 trial · 4 indications
The primary outcome will look at the safety and tolerability of KB301 through the collection and quantification of adverse events, physical examinations, vital signs and clinical laboratory tests.
| Arm | Type | Description |
|---|---|---|
| KB301 | ACTIVE_COMPARATOR | non-integrating HSV-1 vector expressing human type III collagen |
| Placebo | PLACEBO_COMPARATOR | sterile isotonic saline |
| Name | Type | Description |
|---|---|---|
| KB301 | BIOLOGICAL | non-integrating HSV-1 vector expressing human type III collagen |
| Placebo | OTHER | sterile isotonic saline |
Inclusion Criteria: 1. Male or female in good general health, as determined by the investigator, aged ≥18 and ≤75 at the time of consent (only females for Cohort 4) 2. Regions of suitable skin to be selected as Target Area(s), as determined by a physical examination conducted by the investigator du...
KB301 is an investigational therapy being developed for the treatment of skin roughness, wrinkles, fine lines, and skin thickness issues. It is currently in Phase 1 clinical development for these dermatological conditions.
KB301 is designed to express human type III collagen (COL3) in the skin. It is a replication-incompetent, non-integrating vector that delivers the COL3 gene to target cells, potentially addressing skin roughness and related conditions.
KB301 is being developed by Krystal Biotech, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol KRYS. The company is conducting clinical trials to evaluate the safety and efficacy of KB301.
KB301 is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 study is active but not recruiting participants.
KB301 is being studied in a Phase 1 clinical trial with the identifier NCT04540900. This trial is evaluating the therapy for skin roughness, wrinkles, fine lines, and skin thickness in healthy volunteers aged 18 years and older in the United States.
KB301 is a gene therapy that expresses human type III collagen (COL3) in the skin. It is designed to deliver the COL3 gene to target cells, potentially improving skin conditions such as roughness and fine lines.